💡 Microplate Dx (@MicroplateDx), Glasgow's diagnostic tech star, secures £2.5M! Revolutionizing UTI treatment with rapid antibiotic testing. 🔬🇬🇧 👇Dive Deeper👇 🚀 Investment Details: Microplate Dx raised £2.5M in Seed funding. 🤝 Key Investors: Existing backers include Deepbridge Capital LLP (@DeepbridgeCap) and University of Strathclyde (@UniStrathclyde), and new participants Scottish Enterprise (@scotent), SIS Ventures (@sis_ventures) , and Thairm Bio. 🔬 Platform Purpose: Their tech enables quick identification of effective antibiotics, facilitating superior patient treatment. 🎯 Initial Focus: The company is primarily targeting UTIs, already boasting numerous successful clinical studies. ⏰ Rapid Results: Their device provides results within an hour after inserting a urine sample into the cartridge. 📅 Future Outlook: Using this fund, they aim to continue clinical trials in 2024/25 and subsequently launch in European pharmacies, while also eyeing the US market. 🔍 Deep Dive: Behind the Scenes 🔍 🏛 Origins: Spun out from University of Strathclyde in 2022, Microplate Dx was initiated by Dr. Stuart Hannah, Professor Damion Corrigan, Professor Paul Hoskisson, and Dr. Poonam Malik. 🎓 Location & Team: Situated at the University of Strathclyde, they currently employ 12 individuals but have aspirations to increase their team size by roughly 25% within a year. 🌟 Recognition: They were among 12 startups chosen for the AI Accelerator Programme, a collaboration between the Bayes Centre, Edinburgh Innovations at the University of Edinburgh, and their partners. 📊 Significance of UTIs: UTIs rank among the prevalent bacterial infections globally. Roughly 92 million individuals experience UTIs yearly, and in the UK, these infections account for 13.7% of antibiotics prescribed in the NHS's community practice.